ReviewTrends in molecular medicine2020
Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.
Review in Trends in molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 36 citations in OpenAlex.
- Trial
- Distinct T and innate-like lymphocyte reprogramming following lyophilized fecal microbiota transplantation in recurrentGut microbes · 2026Article
- Recent advances and clinical relevance of microbiome dynamics in health and disease.Gut microbes · 2026Review
- Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy.Nature communications · 2026Review
- Observational
- Chimeric vaccine based on Iraqi HLA alleles against a predominant localFrontiers in immunology · 2026Article
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Integrative analysis of intestinal flora and untargeted metabolomics in attention-deficit/hyperactivity disorder.Frontiers in microbiology · 2025Article
- Factors associated with failure of fecal microbiota transplant for recurrentTherapeutic advances in gastroenterology · 2025Article
- Understanding host immune responses iniMeta · 2024Review
- Fecal microbiota transplantation stimulates type 2 and tolerogenic immune responses in a mouse model.Anaerobe · 2024Article
- Article
- Butyrate Protects against Clostridium difficile Infection by Regulating Bile Acid Metabolism.Microbiology spectrum · 2023Article
- Host Immunity and Immunization Strategies for Clostridioides difficile Infection.Clinical microbiology reviews · 2023Review
- Fecal Microbiota Transplantation in Inflammatory Bowel Disease.Biomedicines · 2023Review
- Efficacy of Faecal Microbiota Transplantation for the Treatment of Autism in Children: Meta-Analysis of Randomised Controlled Trials.Evidence-based complementary and alternative medicine : eCAM · 2023Review
- Immunological mechanisms of fecal microbiota transplantation in recurrentWorld journal of gastroenterology · 2022Review
- Different Alterations in Gut Microbiota betweenNutrients · 2022Article
- Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021.Frontiers in cellular and infection microbiology · 2022Article
- Fecal Microbiota Transplant in Severe and Non-SevereJournal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Our understanding and utilization of fecal microbiota transplantation (FMT) has jump-started over the past two decades. Recent technological advancements in sequencing and metabolomics have allowed for better characterization of our intestinal microbial counterparts, triggering a surge of excitement in the fields of mucosal immunology and microbiology. This excitement is well founded, as demonstrated by 90% relapse-free cure rates in FMT treatment for recurrent Clostridioides difficile infections. Growing evidence suggests that in addition to bacterial factors, the host immune response during C. difficile infection greatly influences disease severity. In this review, we discuss recent advancements in understanding the interplay between immune cells and the microbiota and how they may relate to recovery from C. difficile through FMT therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.